Table 2.
Technologies developed by R01 and U01 awardees. Similar to Table 2, we were not able to include all projects – it will make the table too exhaustive. We selected the most unique projects and those which progressed to more advanced levels of maturity. The references included in the table are not necessarily the most recent ones for the particular technology; they represent the status of work during the time the investigator was holding the grant. Last column in the table lists the company(ies) which licensed the technology for future commercialization and clinical trial number, if one is being conducted for the technology.
| Cancer Application | Investigator/Institution | Publications | Clinical Translation Status (Companies and Trials) |
|---|---|---|---|
| Diagnostics and imaging | |||
| Devices for circulating tumor cell capture and purification based on thermoresponsive NanoVelcro templates | Hsian-Rong Tseng and Edwin Posadas UCLA/Cedars-Sinai |
(Grossman et al., 2017; Lin et al., 2014) | Cytolumina |
|
Rodent eye as a non-invasive window for
understanding of cancer nanotherapeutics |
Kit Lam UC Davis |
(Goswami et al., 2019) | |
| Imaging of nanotherapeutic drug action | Ralph Weissleder Harvard University |
(Miller & Weissleder, 2017) | VisEn Medical |
| Magnetoresistive sensor platform for parallel cancer marker detection | Mark Porter University of Utah |
(Young, Blackley, Porter, & Granger, 2016) | |
| Nanotechnology platform for pediatric brain cancer imaging and therapy | Miqin Zhang University of Washington |
(Fang & Zhang, 2010) | |
| Therapeutics | |||
| Nanoscale metal-organic frameworks (nMOFs) and coordination polymers (NCPs) for radiodynamic and immunotherapeutic treatment of solid tumors | Wenbin Lin and Ralph Weichselbaum University of Chicago |
(C. He, Duan, et al., 2016; K. Lu et al., 2018) | RiMO Therapeutics, Coordination Pharmaceuticals NCT03444714, NCT03781362 |
| Mesoporous silica nanoparticles for pancreatic cancer treatment | Andre Nel and Huan Meng UCLA |
(J. Lu et al., 2017) | Westwood Bioscience |
| Theranostic nanoparticles for targeted therapy of pancreatic cancer | Lily Yang Emory University |
(Huang et al., 2016) | |
| RNA nanotechnology in cancer therapy | Peixuan Guo Ohio State University |
(Haque & Guo, 2015; Jasinski, Haque, Binzel, & Guo, 2017) | NanoBio Delivery Pharmaceutical |
| Treatment of glioblastoma using chain-like nanoparticles | Efstathios Karathanasis Case Western University |
(Karathanasis & Ghaghada, 2016) | |
| Targeted therapeutics for ovarian cancer and its microenvironment | Gabriel Lopez-Berestein MD Anderson Cancer Center |
(Kanlikilicer et al., 2017) | |
| Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology | Nicole Steinmetz UC San Diego/Case Western University |
(Hoopes et al., 2018) | |
| Nanovaccine platforms to combat pancreatic cancer | Balaji Narasimhan Iowa State University |
(Banerjee et al., 2018) | |
| STING-activating polymeric nanovaccines for T cell therapy of melanoma | Jinming Gao UT Southwestern |
(Luo, Samandi, Wang, Chen, & Gao, 2017) | OncoNano Medicine |
| High capacity nanocarriers for cancer chemotherapeutics | Alexander Kabanov UNC Chapel Hill |
(Han et al., 2012; Z. He et al., 2016) | |
| Nanoconjugate based on polymalic acid for brain tumor treatment | Julia Ljubimova Cedars-Sinai |
(Patil et al., 2012) | Arrogene |
| Targeting SYK kinase in B-lineage acute lymphoblastic leukemia (ALL) with CD19-specific C-61 nanoparticles | Fatih Uckun USC |
(Uckun & Qazi, 2014) | |
| Combinatorial nanoplatforms to overcome tumor drug resistance | Mansoor Amiji Northeastern University |
(Ganta & Amiji, 2009; X. Yang et al., 2015) | Nemucore Medical Innovations |
| Toxicity and efficacy of gold nanoparticle photothermal therapy in cancer | Dong Shin Emory University |
(Ali et al., 2017) | |
| Tumor targeted nanobins for the treatment of metastatic breast and ovarian cancer | Thomas O’Halloran Northwestern University |
(S.-M. Lee, O’Halloran, & Nguyen, 2010) | |
| Peptide-directed protocells and virus-like nanoparticle platforms | Cheryl Willman and Jeff Brinker University of New Mexico |
(Ashley et al., 2011) | |
| Preclinical platform for theranostic nanoparticles in pancreatic cancer | Naomi Halas Rice University |
(W. Chen et al., 2014) | Nanospectra Biosciences |
| Photodestruction of ovarian cancer: ErbB3 targeted aptamer-nanoparticle conjugate | Tayyaba Hasan Mass. General Hospital |
(Rai et al., 2010) | Visudyne licensed to Bausch and Lomb |
| Multifunctional nanoparticles in diagnosis and therapy of pancreatic cancer | Paras Prasad SUNY-Buffalo |
(Yong et al., 2009) | Licensed to Nanobiotix |
| Near-infrared fluorescence nanoparticles for targeted optical imaging | Chun Li MD Anderson Cancer Center |
(Zhang et al., 2011) | Carestream Health |
| DNA-linked dendrimer nanoparticle systems for cancer diagnosis and treatment | James Baker University of Michigan |
(Myc et al., 2010) | Avidimer |
| Hybrid nanoparticles in imaging and therapy of prostate cancer | Kattesh Katti University of Missouri |
(Chanda et al., 2010) | Nanoparticle Biochem Inc. |